Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wogonin is an O-methylated flavone and a flavonoid-like chemical compound primarily found in the root of the herb Scutellaria baicalensis. It exhibits multiple pharmacological activities including anti-inflammatory, antioxidant, anxiolytic without sedative or muscle-relaxing effects typical of benzodiazepines, anticonvulsant properties, and potential antitumor effects. Wogonin acts as a positive allosteric modulator at the benzodiazepine site of the GABAA receptor with moderate affinity (Ki ~0.92 μM), significantly less potent than diazepam but with lower toxicity (LD50 in mice ~3.9 g/kg). It also inhibits inflammatory mediators such as COX-2 and TNF-alpha by blocking phosphorylation pathways like p38 MAPK and JNK. Wogonin has shown chondroprotective effects by suppressing matrix-degrading enzymes (MMPs) relevant to osteoarthritis treatment and has been studied for topical application in joint diseases. It is under clinical trial investigation as an anti-cancer agent in China.[1][2][3][7][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wogonin.